Navigation Links
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Date:6/19/2009

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show the benefit of lestaurtinib in this patient population when given in sequence with standard induction chemotherapy compared to those treated with standard induction chemotherapy alone. An analysis of the study showed that patients who were treated with lestaurtinib showed similar rates of complete response but no increased benefit in overall survival, compared to those who received induction chemotherapy alone.

"We are disappointed that this study with lestaurtinib did not demonstrate a benefit for this patient population but we remain committed to oncology clinical research and developing innovative therapies for life-threatening diseases," said Dr. Lesley Russell, Executive Vice President and Chief Medical Officer at Cephalon.

The results of this study in relapsed AML will be submitted for presentation at a future medical meeting. The outcome of this study has no impact on the company's previously issued financial guidance for 2009.

"We made a significant financial investment in this pioneering effort to develop lestaurtinib for this molecularly targeted patient population with a poor prognosis and few treatment options," said Frank Baldino, Jr., Ph.D., Cephalon founder, chairman and CEO. "Patients with life-threatening diseases need companies like Cephalon to make that investment and take that risk if we are to improve patient outcomes and the overall cost of healthcare."

Developed by Cephalon scientists, lestaurtinib is a potent inhibitor of several tyrosine kinases including FLT3 and a Janu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
2. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
3. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
9. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
10. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
11. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... VIENNA , March 5, 2015 ... Aloka Medical Ltd., Tokyo, Japan , ... extraordinary compact, portable Ultrasound Bone Densitometry System at the ... to see and test EggQus at the Hitachi Medical ... http://photos.prnewswire.com/prnh/20150305/732754-a ) ,      (Photo: ...
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Vanda ... today announced top-line results of the Phase II ... and efficacy of tradipitant as a monotherapy in ... atopic dermatitis. Despite a highly significant and clinically ... from baseline, p<0.0001) as measured on a 100mm ...
(Date:3/4/2015)... MENLO PARK, Calif. , March 4, 2015 /PRNewswire/ ... biotechnology company in the emerging field of regenerative medicine, ... Chief Executive Officer, will ring The Opening Bell ® ... Thursday, March 5, 2015. Asterias began trading as an ... "New York Stock Exchange is a trusted ...
Breaking Medicine Technology:Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 2Hitachi Aloka Medical, Ltd. Introduces EggQus AOS 100E - a Compact and Lightweight Ultrasound Bone Densitometry System 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... on November 1, 2008 at 2008 iSBTc ... Annual Meeting ... a clinical-stage biopharmaceutical company focused on,oncology, today announced that it has completed ... treatment of,advanced melanoma. CuraGen also announced today that Phase II results from,this ...
... As a surgeon and clinical,instructor, Dr. Jeffery ... number of patients contracting ... and dying from ... that infections are quickly,spreading beyond the healthcare system ... 2004 study supervised by Dr. Deal tracked 13,510 ...
Cached Medicine Technology:CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma 2CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma 3CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma 4Doctor Declares War on Hospital Infections, Patents MRSA-Killing Machine 2
(Date:3/5/2015)... 05, 2015 Jordan Valley Medical Center ... a treatment option for sudden cardiac arrest. When a ... and can detect any life-threatening abnormalities. If an abnormal ... patient before delivering a treatment shock to restore normal ... of Jordan Valley Medical Center and the Heart and ...
(Date:3/5/2015)... Kevin Batsford lost his brother in ... drug addiction. The siblings frequented bridges, highways, and obscure ... seek refuge during the night. Batsford said that is ... his outward appearance, hygiene, or overall well being- outside ... reported on Feb. 23rd that Batsford left behind ...
(Date:3/5/2015)... IL (PRWEB) March 05, 2015 The ... announce their sponsorship of the upcoming Crain’s Chicago Business ... , The Physicians' Breakfast will take place from 7:30 ... East Pearson Street, Chicago, IL 60611. The morning’s events ... Chicago’s top healthcare professionals. , The panel discussion ...
(Date:3/5/2015)... The recent influx of online ... alarming, with more and more internet ads offering “prescription” ... making it easy for more people to fall prey ... and endanger their health. The company urges consumers to ... diet pills: , 1.    Where are the products manufactured and ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Colorful packaging ... breakfast cereals are best for health. But all it ... what to look for, reports the March 2015 ... a plan," says Kathy McManus, director of the Department ... for a cereal that hits all the markers of ...
Breaking Medicine News(10 mins):Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 3Health News:The Homeless’ Unaddressed Drug Addiction Continues to Spiral Out of Control, Harbor Village Detox Stresses Treatment for the Homeless 2Health News:The Homeless’ Unaddressed Drug Addiction Continues to Spiral Out of Control, Harbor Village Detox Stresses Treatment for the Homeless 3Health News:Cook County Law Firm to Sponsor Physicians Breakfast 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:Tips to Find the Healthiest Breakfast Cereals, From the March 2015 Harvard Health Letter 2
... Corder of the William Harvey Research ... test with dark chocolate on heart ... the medical trial once he gets ... forty patients with cardiovascular disease will ...
... the UN system in Africa on Tuesday launched the Acceleration ... prevention matters were the top priority at the launch of ... aims to curb the spread on the pandemic, especially in ... said at a launching ceremony, held at the AU headquarters, ...
... poultry worker in West Sumatra is infected with the ... in Indonesia to 33// , a health ministry official ... WHO Tuesday morning," said Hariyadi Wibisono, director general of ... poultry worker, identified as Achyan, was being treated in ...
... have diabetes. New South Wales (NSW) has recorded a 300% ... past 10 years. Experts have asked the health system and ... if it continues it is expected that about 2 million ... this increase is that of the diet and lifestyle factors. ...
... hospital at an estimated cost of Rs.1 billion to ... ,The hospital will also have an attached ... headquarters of Bastar district. ,Chief Minister Raman ... for the medical college during the current fiscal, a ...
... Nelson, a neurologist and study author of the University of ... more likely to mix up dreams and reality than those ... many people report out-of-body experiences, seeing intense lights, or a ... are more common than people realize. Nelson began investigating the ...
Cached Medicine News:Health News:African Union Launches A Programme On Acceleration of HIV Prevention 2Health News:Its High Time the Australian Government Takes Steps against Diabetes 2Health News:Are Near death Experience Really Just A Dream 2
... smallest blood glucose testing system available. The Sidekick ... in your backpack or briefcase, your sports ... or pocket.* Its small size makes it convenient ... so convenient it's easier for you to test ...
... expanding the borders of stereomicroscopy with ... reproduction, high-contrast images and significantly more ... improved resolution and contrast. The innovative ... combines all essential functions of a ...
Inquire...
Inquire...
Medicine Products: